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SCIENTIFIC EDITORIAL
Personalized  antiplatelet  therapy:
The wrong  approach?
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The GRAVITAS  (Gauging  Responsiveness  with  A  VerifyNow  assay—Impact  on  Thrombosis  And
Safety)  study  has  demonstrated  the  detrimental  impact  of  high  on-treatment  platelet  reac-
tivity  following  stent  implantation  and  the  failure  of  a  double  clopidogrel  maintenance  dose
to  reduce  cardiovascular  events  in  patients  deemed  clopidogrel  non-responders  (Fig.  1)
[1].  However,  there  was  still  evidence  after  the  GRAVITAS  study  to  support  personalized
medicine-based  on  platelet  reactivity.  The  combination  of  a  low-risk  population  together
with  platelet  reactivity  assessment  after  percutaneous  coronary  intervention  (PCI)  was
recognized  as  a  relevant  limitation  that  may  have  accounted  for  the  negative  results  of
the  GRAVITAS  study.
The  TRIGGER-PCI  (Testing  Platelet  Reactivity  in  Patients  Undergoing  Elective  Stent
Placement  on  Clopidogrel  to  Guide  Alternative  Therapy  with  Prasugrel)  study  design  was
similar  to  that  of  the  GRAVITAS  study,  but  treatment  intervention  was  more  aggressive,
using  prasugrel  instead  of  an  increased  clopidogrel  maintenance  dose  (Fig.  1).  The  study
was  stopped  prematurely  due  to  a  low  event  rate  [2].
Platelet  reactivity  has  been  consistently  reported  as  an  independent  predictor  of  ‘hard’
post-PCI  endpoints,  including  stent  thrombosis,  myocardial  infarction  and  cardiovascular
mortality  (Fig.  2)  [3,4]. Notably,  the  hazard  associated  with  high  platelet  reactivity  is
greater  in  patients  with  an  acute  coronary  syndrome  (ACS)  than  in  patients  undergoing  PCI
for  stable  angina;  it  accounts  for  approximately  60%  of  the  deﬁnite/probable  stent  throm-
bosis  events,  demonstrating  the  dominant  contribution  that  inadequate  P2Y12 receptor
inhibition  makes  to  thrombotic  events  [5,6].  As  a  consequence,  the  bedside  platelet  func-
tion  test  has  become  an  opportunity  to  guide  antiplatelet  therapy,  particularly  when  there
is  an  unexpected  complication.  This  is  also  the  case  when  new  P2Y12 inhibitors  are  not
available,  in  the  absence,  however,  of  a  recommendation  for  this  type  of  use  [7,8].
Abbreviations: ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CI, conﬁdence interval; HR, hazard ratio; NSTE-ACS,
non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention.
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Figure 1. Design and results of the GRAVITAS and TRIGGER-PCI
trials. CI: conﬁdence interval; Clopi: clopidogrel; CV: cardiovascu-
lar; FU: follow-up; HR: hazard ratio; MI: myocardial infarction; PCI:
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Figure 2. Platelet reactivity as a marker of risk in patients who
underwent percutaneous coronary intervention. HR: hazard ratio;
HPR: high platelet reactivity; HRPR: high residual platelet reactiv-
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percutaneous coronary intervention; PRU: P2Y12 reaction units; ST:
tent thrombosis.
The  ARCTIC  (Assessment  with  a  double  Randomization  of
1]  a  ﬁxed  dose  versus  a  monitoring-guided  dose  of  aspirin
nd  Clopidogrel  after  drug-eluting  stent  implantation  and
2]  Treatment  Interruption  versus  Continuation,  1  year  after
tenting)  multicentre  randomized  study  sought  to  determine
hether  a  strategy  based  on  systematic  platelet  function
esting  to  tailor  antiplatelet  therapy  is  superior  to  standard
are  in  2440  patients  with  stable  angina  or  non-ST-segment
levation  ACS  (NSTE-ACS)  undergoing  PCI  [9].  In  contrast  to
he  GRAVITAS  trial,  this  study  randomized  the  use  of  platelet
unction  testing  with  treatment  intervention  (monitoring
a
s
rty; LRPR: low residual platelet reactivity; LTA: light transmission
ggregometry.
rm)  versus  standard  of  care  according  to  clinician’s  pref-
rence  without  platelet  function  test  (conventional  arm)
Fig.  3).  In  the  monitoring  arm,  serial  platelet  function
ests  (before  stent  implantation  and  during  the  maintenance
hase)  and  treatment  adjustments  using  a  predeﬁned  treat-
ent  algorithm  were  performed.  In  addition  to  treatment
ntensiﬁcation  due  to  high  on-treatment  platelet  reactivity,
atients  could  be  switched  back  from  prasugrel  to  clopido-
rel  after  PCI  if  low  on-treatment  platelet  reactivity  was
easured.  Despite  halving  the  rate  of  high  platelet  reactiv-
ty  to  adenosine  diphosphate  (Fig.  4),  the  primary  endpoint
f  death,  myocardial  infarction,  stent  thrombosis,  stroke  or
rgent  revascularization  was  similar  after  1  year  with  the
wo  strategies  (hazard  ratio  [HR]  1.13,  95%  conﬁdence  inter-
al  [CI]  0.98—1.29;  p  =  0.10).
The  take-home  message  is  that  platelet  reactivity  is
ot  only  a measure  of  drug  response,  but  also  integrates
he  effect  of  response  to  P2Y12 receptor  antagonists  and
omorbidities,  such  as  advanced  age,  diabetes  and  renal
nsufﬁciency.  Platelet  reactivity  should  also  be  consid-
red  as  a  surrogate  marker  for  studies  on  antiplatelet
reatments  that  may  be  helpful  to  explain  the  results
f  trials.  This  has  been  conﬁrmed  by  the  prespeciﬁed
harmacodynamic  TRILOGY-ACS  (A  Comparison  of  Prasug-
el  and  Clopidogrel  in  Acute  Coronary  Syndrome  Subjects
ith  Unstable  Angina/Non-ST-Elevation  Myocardial  Infarc-
ion  Who  Are  Medically  Managed)  study,  which  demonstrated
 real  effect  of  treatment  intensiﬁcation  but  a  lack  of
ndependent  relationship  between  platelet  reactivity  and
linical  outcome  [10]. Such  results  further  support  the  lack
f  beneﬁt  of  intensiﬁcation  of  antiplatelet  therapy  in  med-
cally  managed  patients  [11]  (Fig.  5).
What  is  the  future  of  platelet  function  testing?  The  level
f  recommendation  for  routine  platelet  function  testing  in
atients  who  undergo  stent  placement  will  remain  low  in
ccordance  with  the  negative  results  of  recent  randomized
tudies  (Table  1) [1,2,9].  Platelet  activity  rather  appears  as  a
eliable  risk  stratiﬁcation  approach  but  not  as  a  modiﬁable
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Figure 3. The ARCTIC trial design. ASA: acetylsalicylic acid (aspirin); FU: follow-up; GP: glycoprotein; MI: myocardial infarction; PCI:
percutaneous coronary intervention; Rd: randomization.
risk  factor  that  may  help  to  guide  therapy.  However,  the
ARCTIC  study  has  evaluated  neither  the  accuracy  of  platelet
function  testing  speciﬁc  to  the  treatment  effect  of  P2Y12
inhibitors,  such  as  vasodilator-stimulated  phosphoprotein
(VASP),  nor  the  combination  of  fast  genotyping  with  platelet
function  testing  in  clopidogrel-treated  patients.  Fast  geno-
typing  is  now  available  to  identify  clopidogrel  metabolizer
Figure 4. The effect of treatment adjustment in the monitor-
ing arm on the rate of clopidogrel and aspirin non-responders. MD:
maintenance dose.
proﬁle  and  guide  P2Y12 inhibition  strategy,  especially  in  ACS
patients  [12,13],  with  the  possibility  of  having  patients  in
a  prespeciﬁed  window  of  platelet  inhibition  to  avoid  both
bleeding  and  ischaemic  events.  In  the  ARCTIC  study,  half  of
the  patients  were  genotyped;  whether  there  is  a  signiﬁcant
interaction  between  treatment  monitoring  and  clopidogrel
metabolizer  proﬁle  may  generate  new  research  hypotheses.
Low  platelet  reactivity  has  been  associated  with  major
bleeding,  a  common  complication  of  the  more  potent
P2Y12 inhibitors  and  a  strong  determinant  of  cardiovascu-
lar  mortality.  In  the  ARCTIC  study,  treatment  monitoring
was  associated  with  a  non-signiﬁcant  reduction  in  major
Figure 5. Primary endpoint of the ARCTIC trial. HR: hazard ratio.
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Table  1  Clinical  guideline  recommendations  regarding  platelet  function  testing.
Guideline  Statement  CoR  LoE
ESC  PCI  guidelines
2005
The  emerging  question  of  possible  clopidogrel  resistance
requires  more  investigations
— —
ACC/AHA/SCAI  PCI
guideline  2005
In patients  in  whom  subacute  thrombosis  may  be  catastrophic
or  lethal  (unprotected  left  main,  bifurcating  left  main  or  last
patent  coronary  vessel),  platelet  aggregation  studies  may  be
considered
IIb  C
ESC  guidelines  on
myocardial
revascularization
2010
Monitoring  of  antiplatelet  response  by  platelet  function  assays
is  currently  used  for  clinical  research,  but  not  in  daily  clinical
practice
III C
ESC  NSTE-ACS
guidelines  2011
Platelet  function  testing  may  be  considered  in  selected  cases
when  clopidogrel  is  used.  Several  trials  currently  under  way
may  clarify  the  impact  of  adapting  therapy  on  the  basis  of  the
results  of  platelet  reactivity  assays,  but,  so  far,  the  routine
clinical  use  of  platelet  function  tests  in  clopidogrel-treated
patients  with  ACS  cannot  be  recommended
IIb B
ACC/AHA/SCAI  PCI
guidelines  2011
Platelet  function  testing  may  be  considered  in  patients  at  high
risk  for  poor  clinical  outcomes.  In  patients  treated  with
clopidogrel  with  high  platelet  reactivity,  alternative  agents,
such  as  prasugrel  or  ticagrelor,  might  be  considered.  The
routine  clinical  use  of  platelet  function  testing  to  screen
patients  treated  with  clopidogrel  who  are  undergoing  PCI  is
not  recommended
IIb C
ACCF/AHA
UA/NSTEMI
guidelines  2012
Platelet  function  testing  to  determine  platelet  inhibitory
response  in  patients  with  UA/NSTEMI  (or  after  ACS  and  PCI)  on
P2Y12 receptor  inhibitor  therapy  may  be  considered  if  results
of  testing  may  alter  management
IIb B
ESC  STEMI  guidelines
2012
No speciﬁc  recommendation  —  —
ACCF/AHA  STEMI
guidelines  2013
The  roles  of  platelet  function  testing  and  genetic  screening
for  clopidogrel  metabolism  in  the  acute  phase  of  STEMI  care
are  uncertain
— —
ACC: American College of Cardiology; ACCF: American College of Cardiology Foundation; ACS: acute coronary syndrome; AHA: American
Heart Association; CoR: class of recommendation; ESC: European Society of Cardiology; LoE: level of evidence; NSTE-ACS: non-ST-
segment elevation acute coronary syndrome; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary
intervention; SCAI: Society for Cardiovascular Angiography and Interventions; STEMI: ST-segment elevation myocardial infarction; UA:
unstable angina.
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Nnd  minor  bleeding  (3.1%  versus  4.5%,  HR:  0.69;  95%  CI:
.46—1.05;  p  =  0.08).  We  may  therefore  expect  that  bleed-
ng  in  patients  at  low  ischaemic  risk  may  be  the  future  of
reatment  monitoring.  This  is  in  line  with  a  recent  inves-
igation  of  bleeding  risk  in  patients  undergoing  coronary
rtery  bypass  graft  (CABG)  surgery.  A  strategy  based  on
reoperative  platelet  function  testing  to  determine  the  tim-
ng  of  CABG  in  clopidogrel-treated  patients  was  associated
ith  the  same  amount  of  bleeding  observed  in  clopidogrel-
aive  patients  and  a  waiting  time  that  was  approximately
0%  shorter  than  that  recommended  in  current  guidelines
14].  These  results  led  to  an  upgrade  in  the  guidelines,
o  base  timing  of  surgery  on  platelet  function  monitoring
ather  than  the  arbitrary  use  of  a  speciﬁed  period  of  delay
15].
e
s
i
rPersonalized  antiplatelet  therapy  is  looking  at  the  patient
ith  a  different  approach  to  the  routine  clinical  approach.
t  is  not  a  wrong  approach  per  se.  We  are  just  at  the
eginning  of  the  story  and  platelet  function  monitoring
hould  be  envisioned  as  an  attractive  approach  to  reﬁning
ntiplatelet  strategy  in  gravely  ill  and  fragile  patients.  This
s  the  speciﬁc  objective  of  the  ongoing  ANTARCTIC  (Assess-
ent  of  a Normal  versus  Tailored  dose  of  prasugrel  After
tenting  in  patients  aged  >  75  years  to  Reduce  the  Composite
f  bleeding,  stent  Thrombosis  and  Ischemic  Complications;
CT01538446)  trial,  which  is  looking  at  the  net  clinical  ben-
ﬁt  of  P2Y12 inhibition  in  elderly  ACS  patients  who  undergo
tent  implantation  (Fig.  6).  What  we  need  is  the  right  test
n  the  right  population  with  the  right  antiplatelet  dosing
egimen.
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Figure 6. The ANTARCTIC trial design. ACS: acute coronary syndrome; BARC: Bleeding Academic Research Consortium; CV: cardiovascular;
I: peMACE: major adverse cardiac events; MI: myocardial infarction; PC
years old.
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